Skip Navigation

Skip Navigation

Issue No. 1  | January 05, 2007
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

AIDSinfo to Exhibit at NBC4 Health and Fitness Expo

AIDSinfo is proud to participate in The NBC4 Health and Fitness Expo at the Washington Convention Center in Washington, DC, January 13-14, 2007.

This FREE-to-the-public event is expected to draw more than 80,000 people from the Washington Metropolitan area and offers the public health tests and screenings, including HIV/AIDS screenings.

HIV/AIDS is one of the most severe health problems facing Washington, DC There have been more than 7,000 AIDS-related deaths in the District since 1984. More than 9,000 people with AIDS live in the city, according the DC Department of Health.

Our AIDSinfo health information specialists will be on hand at The NBC4 Health and Fitness Expo (Booth 3031) to provide reliable HIV/AIDS-related information on treatment, clinical trials, and research.

If you're in the neighborhood, come to The NBC4 Health and Fitness Expo. Don't forget to stop by the AIDSinfo booth and say hello. For more information call us at 1-800-448-0440.


MK-0158, TMC125, and Maraviroc Now Available Through Expanded Access

In the September 15, 2006, At-a-Glance newsletter, AIDSinfo highlighted two anti-HIV medications available through expanded access. The Food and Drug Administration's expanded access programs provide patients with limited treatment options a way to add investigational medications to their treatment regimen. Now, in addition to MK-0158 and TMC125, a third anti-HIV medication has been made available through expanded access: maraviroc. 

  

Maraviroc is a CCR5 antagonist.  CCR5 is a protein found on the surface of certain immune cells that the HIV virus uses to enter the cell.  CCR5 antagonists inhibit HIV from entering immune cells.

 

MK-0158, TMC125, and maraviroc are expected to be approved in 2007.


 


 


 


 


 


 


 


 


Twitter - Stay connected FaceBook - Stay connected
ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228